Blog · By IVF Automation team · 25 Oct 2026
The biggest time-lapse trial found no live-birth gain. Here's the real case for buying one.
Time-lapse incubators are on the wish list of many Indian IVF labs, and they are often the first step towards AI embryo-ranking software. Vendor brochures and clinic websites frequently present them as a way to "choose the best embryo".
The evidence now says something more specific. In July 2024, The Lancet published the TILT trial, a double-blind randomised trial of 1,575 participants at seven IVF centres in the UK and Hong Kong. Its conclusion: using time-lapse imaging for embryo culture and selection "does not significantly increase the odds of live birth compared with standard care". ESHRE and the UK regulator, the HFEA, have reached the same position. Yet the same bodies describe real laboratory benefits. This guide separates the two, so a lab manager can make a purchase case on operations, not on promises. It is general operational information, not medical advice.
What a time-lapse system actually does
A time-lapse incubator has a built-in camera that photographs each embryo at regular intervals, typically every 5 to 15 minutes according to ESHRE's time-lapse working group. Embryologists can review development as a video without taking dishes out of the incubator. Some systems add software that annotates the timing of cell divisions (morphokinetics) and ranks embryos, and newer tools apply AI models to the same images.
That makes time-lapse a data system as much as an incubator. Every culture run produces thousands of images and annotation records that need storage, backup, access control and links to the patient record.
What the evidence says about outcomes
- TILT (Lancet, 2024). Participants were randomised into three groups: time-lapse with embryo selection, time-lapse for undisturbed culture only, and standard incubation. Live birth rates were 33.7%, 36.6% and 33.0% respectively, with no significant difference. Clinical pregnancy and pregnancy loss also showed no significant differences, according to the NHS Health Research Authority summary.
- Cochrane review (2019). Armstrong and colleagues pooled nine randomised trials covering 2,955 couples. They found insufficient good-quality evidence of differences in live birth, miscarriage, stillbirth or clinical pregnancy between time-lapse, with or without selection software, and conventional incubation. The evidence was rated low to very low quality.
- ESHRE add-ons guidance (2023). ESHRE's good practice recommendations on add-ons state that "time-lapse imaging is not recommended as a tool to improve live birth rates". They also note that embryo selection algorithms "appear to be laboratory dependent", probably because culture conditions differ between labs.
- HFEA (UK regulator). The HFEA's add-ons ratings rate time-lapse black for improving the chance of a baby for most patients, both with manual and with automated (algorithm or AI) analysis. Black means moderate or high quality evidence shows no effect on that outcome.
For marketing teams, the implication is direct: claims that time-lapse or AI ranking "improves success rates" are not supported by these sources. Our earlier guide on AI embryo assessment and FDA and CDSCO clearance covers how regulatory status should be described too.
Where the operational case is real
ESHRE's 2023 guidance says time-lapse "provides a tool for research, teaching, standardizing assessment, facilitating laboratory workflows and quality control". Its 2020 working group paper adds that it may allow "better and more flexible management of laboratory workload". These are the benefits a lab can plan and measure:
- Workflow. Assessments do not have to happen at fixed check times beside the incubator, which helps labs with tight staffing or weekend rotas.
- Standardisation and QC. Recorded images let senior embryologists audit grading, compare annotations between staff and track consistency over time. ESHRE recommends naming one or more trained "TLT referents" to own annotation and the QC programme.
- Training. A library of recorded development is a practical teaching resource for junior embryologists.
- Data for future AI. Clean, consistently annotated image data is the foundation for any AI tool a lab may later evaluate, and for checking whether an algorithm built elsewhere behaves the same way in your lab.
ESHRE's 2023 guidance also notes that these functions are not considered an add-on when patients are not charged extra for them. That matters for how clinics price and describe the service.
A buyer's checklist, built on ESHRE's 11 recommendations
ESHRE's working group lists 11 recommendations for clinics before getting started. Turned into vendor and internal questions, they look like this:
- Why are we buying it? Write down the purpose, such as workload, QC or teaching, and how you will measure it.
- Total cost. Include hardware maintenance, software upgrades, dedicated dishes and the AMC. Our AMC questions for equipment vendors apply here.
- Will morphokinetics be used for selection, deselection or ranking? Decide which parameters, from the literature, and how you will monitor them.
- Fit with your culture system. Gas type, humidity, footprint, capacity, dish type and supply chain in India.
- Support. How quickly can an engineer and an application embryologist reach your city?
- Installation and training from the manufacturer or distributor, in writing.
- A user requirement checklist that you score each shortlisted system against.
- Settings validation once installed, before routine use.
- Named TLT referents for annotation and QC.
- Counselling material so clinic staff explain the current evidence accurately.
Add three data questions that ESHRE's list does not spell out but an automation-minded lab should ask. Can images and annotations be exported in an open format, and who owns them? Does the system connect to your EMR or LIMS, or will staff re-type results? Where is data stored, and how will access, backup and breach handling meet India's DPDP Act duties from May 2027?
The bottom line for Indian labs
Treat a time-lapse system as lab infrastructure with a measurable operational return. Do not treat it as a promise to patients. If you later add an AI ranking tool, validate it on your own data and describe it in line with the evidence. Keep the purchase file, validation records and QC logs together. Our QC log tools and ART Act lab compliance checklist help with that record-keeping.
Sources
- Bhide P et al., TILT trial, The Lancet, 2024 and the HRA research summary
- Armstrong S et al., Time-lapse systems for embryo incubation and assessment, Cochrane Database of Systematic Reviews, 2019
- ESHRE Add-ons Working Group, Good practice recommendations on add-ons in reproductive medicine, Human Reproduction, 2023
- ESHRE Working group on Time-lapse technology, Good practice recommendations for the use of time-lapse technology, Human Reproduction Open, 2020
- HFEA, Time-lapse imaging and incubation (add-on rating)
Your next step
Vendors of time-lapse, incubator or lab-data systems can claim a free listing in our directory, so Indian lab managers can find you when they shortlist. Lab teams can browse the vendor discovery page and the workflow library.
General operational information only; not medical, clinical or legal advice. Product and platform names are mentioned for information and are not endorsements. See our disclaimer.